Ingredient guides

Soy isoflavones

Share

Email article

Published

Soy isoflavones are compounds of the soybean, Glycine max, similar in structure to the hormone estrogen. The main ones are genistein, daidzein and glycitein. Supplements contain soy extracts with concentrated isoflavones; some labels and trials name the soy germ as the source. Red clover isoflavones come from another plant and are not covered here.

Terms and sources
similar in structure to the hormone estrogen
NIH National Center for Complementary and Integrative Health (NCCIH), soy page.
genistein, daidzein and glycitein
In soybeans they are bound to a sugar, as genistin, daidzin and glycitin. Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article.
soy extracts with concentrated isoflavones
NCCIH uses the words soy extracts containing concentrated isoflavones.
soy germ
One trial report calls its source soy hypocotyl. Wong et al., American Journal of Clinical Nutrition, 2009.
Red clover
LPI lists red clover extracts apart from soy products.

Soy isoflavones in the body

Soy isoflavones are not nutrients, and the body has no daily requirement for them. Trials in women around menopause measure bone density, hot flashes and symptom scores.

In soybeans, isoflavones are bound to a sugar, as genistin, daidzin and glycitin. Digestion or fermentation releases the sugar, leaving genistein, daidzein and glycitein. In pharmacokinetic studies cited by LPI, blood daidzein and genistein peaked about six hours after intake. Some gut bacteria can turn daidzein into equol, a metabolite with greater estrogenic activity than daidzein. Equol was produced by about 25–30% of adults in Western countries and 50–60% of adults in Asian countries.

Terms and sources
bound to a sugar
These forms are called glycosides. Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article.
leaving genistein, daidzein and glycitein
These free forms are called aglycones.
peaked about six hours
A smaller first peak came about one hour after the meal. LPI ties the later peak to the colon.
equol
Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article.
50–60%
Also by Western adult vegetarians. Measured in urine after soy foods. Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article.

NCCIH, on safety: "Some people are allergic to soy." NCCIH adds: "In the United States, the presence of soy in packaged foods and dietary supplements must be indicated on the product label." NCCIH adds: "In research studies, soy protein supplements have been safely used for up to 16 weeks, and soy extracts containing concentrated isoflavones have been used safely for up to 6 months." NCCIH adds: "Side effects of soy may include bloating, constipation, diarrhea, and nausea."

Terms and sources
on safety
The NCCIH safety section, quoted in full in this paragraph and the next two. NIH National Center for Complementary and Integrative Health (NCCIH), soy page.

NCCIH adds: "Interactions between certain soy products containing high amounts of tyramine (such as tofu and soy sauce), and monoamine oxidase inhibitors (a group of antidepressant drugs) have been reported (i.e., dangerously high blood pressure)." NCCIH adds: "If you take any type of medicine, talk with your health care provider before using soy or other herbal products; some herbs and medicines interact in harmful ways."

Terms and sources
tyramine
An amine found in some foods; this note is ours. NCCIH names tofu and soy sauce.

NCCIH adds: "The use of soy during pregnancy may be unsafe in amounts greater than those commonly found in foods." NCCIH adds: "Little is known about whether it is safe to use soy in amounts greater than those commonly found in foods while breastfeeding."

LPI notes that the long-term safety of very high supplemental doses of soy isoflavones is not yet known.

Terms and sources
LPI notes
Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article. LPI adds that longer-term studies are needed. LPI also cites one study where 100 mg a day for six months was well tolerated by older adults.

LPI notes: "The safety of high intakes of soy isoflavones and other phytoestrogens for breast cancer survivors is an area of concern among scientists and clinicians." LPI adds that "until more is known about potential interactions in humans, those taking tamoxifen or other selective estrogen receptor modulators (SERMs) to treat or prevent breast cancer should be cautious and seek medical advice regarding the use of soy protein supplements or isoflavone extracts."

Terms and sources
LPI notes
Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article. Safety section: subsections on survivors and on drug interactions.

Where soy isoflavones come from

Soybeans have long been cultivated in Asia and are now also produced elsewhere, including the United States. Common soy foods include tofu, miso, tempeh, edamame and soy milk. LPI calls soybeans by far the most concentrated source of isoflavones in the human diet.

Terms and sources
long been cultivated in Asia
NIH National Center for Complementary and Integrative Health (NCCIH), soy page.
tofu, miso, tempeh, edamame and soy milk
NIH National Center for Complementary and Integrative Health (NCCIH), soy page.
by far the most concentrated source
Small amounts are found in other legumes, grains and vegetables. Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article.

In an LPI table, 85 g (3 ounces) of tempeh held 51.5 mg of isoflavones and soft tofu 19.2 mg. Per 99 g (3.5 ounces), a soy protein concentrate made with an alcohol wash held 11.5 mg. One made with a water wash held 94.6 mg.

Terms and sources
LPI table
LPI notes that isoflavone content varies between brands and lots, so the values are only a guide.
alcohol wash
LPI: soy protein isolates made with an ethanol wash generally lose most of their isoflavones. Water-washed ones tend to keep them.

Average intakes are 25–50 mg a day in Japan, China and other Asian countries. LPI cites EPIC data from 10 European countries, with average intakes below 1 mg a day.

Terms and sources
25–50 mg a day
Linus Pauling Institute (LPI), Oregon State University, soy isoflavones article.
10 European countries
24-hour recall data from 36,037 people. LPI adds 2.3 mg a day for the British general population and 19.4 mg for a health-conscious British group.

Daily amounts and the upper limit

United States

There is no US recommended daily amount for soy isoflavones. The National Academies have not set an upper limit for soy isoflavones.

In the NIH label database, 895 US labels list soy isoflavones, and 86% of them list other ingredients too. Another 241 labels list isoflavones not tied to soy; 174 of them name another plant, such as red clover.

Terms and sources
895 US labels
NIH Dietary Supplement Label Database, including products no longer sold. Labels with a row that ties isoflavones, genistein or daidzein to soy. We counted these.
86%
768 of 895. Labels where every row is soy, its isoflavones or a nutrition row are counted as soy isoflavones only.
Another 241 labels
These are not in the counts below. Synthetic isoflavones, such as ipriflavone, are not counted at all. We counted these.

Of 127 labels whose only ingredient is soy isoflavones, 40 state an amount of isoflavones. Another 39 give only the weight of a soy extract, concentrate or powder. Another 39 give one amount under the name soy isoflavones, without saying whether it is the extract or the isoflavones.

Terms and sources
40 state an amount
28 give it on its own row next to the extract weight. 12 give it on a single row named total isoflavones. We counted these.
only the weight
Some of them name isoflavones as a form, without an amount.
one amount under the name soy isoflavones
Such as soy isoflavones, 100 mg. Six more labels give the extract weight and single isoflavones without a total, and 3 give an amount for genistein.

On the 28 labels with both numbers, isoflavones make up 2% to 40% of the extract weight. Of the 127 labels, 41 name genistein, and 32 give a genistein amount.

Terms and sources
2% to 40%
By our calculation: 13 labels 2%, all SoyLife, such as 2 g with 40 mg. 7 labels 4%, 3 labels 2.2–3.1%, and 5 labels about 40%.
41 name genistein
In an ingredient name, a form or a separate row. We counted these.

On 25 labels that name soy germ, hypocotyl or SoyLife, daidzein exceeds genistein on 24. On 48 other labels, genistein exceeds daidzein on 29, and the two are equal on 8. Of the 895 labels, 4 mention aglycones, 62 name NovaSoy and 109 name SoyLife.

Terms and sources
25 labels
Labels among the 895 with mg for a daidzein row and a genistein row. 16 of the 25 name only SoyLife. A typical row pair is 13.4 mg of daidzein and 2 mg of genistein. We counted these.
48 other labels
Daidzein exceeds genistein on the other 11. We counted these.
4 mention aglycones
The word aglycone, or AIE, in a row name or a form. NovaSoy and SoyLife are ingredient brand names. We counted these.

Upper limits in other countries: see the table of limits by country on this page.

Forms of soy isoflavones and how they differ

Extracts differ in the part of the bean they come from and in how much isoflavone they hold. When US isoflavone supplements were tested, about half differed by more than 10% from the amount on the label. One trial's soy germ tablet held 40.51 mg of isoflavones: 22.01 mg daidzein, 13.54 mg glycitein, 4.96 mg genistein. Another trial's tablets held genistein, daidzein and glycitein at 1.3 to 1.0 to 0.3, similar to soybeans, per the report. We do not rank forms.

Terms and sources
how much isoflavone they hold
LPI notes that the amounts in products may vary considerably.
about half
LPI, citing tests by an independent laboratory.
soy germ tablet
Mostly as sugar-bound forms, which the report says reflects the natural composition of the soy germ. Wong et al., American Journal of Clinical Nutrition, 2009.
Another trial's tablets
NovaSoy ingredients, per the report's acknowledgments. Alekel et al., American Journal of Clinical Nutrition, 2010.
Soy germ extract and other soy isoflavone forms
FormWhat it isStudies below
Soy germ extractIsoflavones from the soy germ, rich in daidzein and glycitein in one trial; one trial report calls it soy hypocotylBone density: Wong 2009. Hot flashes: Ye 2012, Khaodhiar 2008.
Soy isoflavone extract, part not namedExtracts with a stated isoflavone amount; Ho 2007 does not name the formBone density: Levis 2011, Alekel 2010. Hot flashes: Ferrari 2009, Nahas 2007, Campagnoli 2005. Thinking tests: Ho 2007.
Aglycones and sugar-bound formsThe same isoflavones with or without the sugarKhaodhiar 2008 used aglycones; no study below compares the two forms.
Foods with added isoflavonesFoods enriched with isoflavonesBone density: Brink 2008.
Soy protein with its isoflavonesSoy protein that keeps its isoflavones; ethanol-washed protein loses most of themNot in the studies below.
Genistein aloneA single soy isoflavoneNot in the studies below.
Red clover isoflavonesIsoflavones from another plantNot in the studies below.

What it is: Wong 2009, Ye 2012 and Khaodhiar 2008 (soy germ). Levis 2011, Alekel 2010, Ferrari 2009, Ho 2007, Nahas 2007 and Campagnoli 2005 (extracts). Brink 2008 (foods). LPI (aglycones, soy protein, genistein, red clover).

Published studies of soy isoflavones

Trials that selected women by low bone density or by a diagnosis are not listed here. The full list of studies not shown is in the note to the summary.

10 studies in women around or after menopause: 3 found a difference, 3 none, 4 mixed, one of them against.

Five selected women by hot flashes or a symptom score. No listed report selected women by a diagnosis or by low bone density. Limited to the 10 largest trials, by the number of women randomized. Not listed for size: a six-woman study of two forms. Not listed: trials that selected women by low bone density or by a diagnosis. Nor those that selected by a clinical range of a measurement. Also not listed: trials where some women took a hormone medicine. Nor trials that added soy protein or exercise in a second factor. Also not listed: soy protein against milk protein, mixtures, red clover, and trials without a dummy group. Also not listed: a trial that does not name the plant source of its isoflavones. Also not listed: a trial with an unread correction and genistein alone with an unstated source. Also not listed: a subgroup of a larger trial and results given only for a subgroup. Nor a report without a comparison with the dummy group. Also not listed: a trial whose abstract gives no entry rules. Second reports of listed trials are not listed either. Nor a report from a trial that another report describes as in women with lower bone mass. Also not listed: reviews whose trial lists we could not read, or that include red clover or synthetic isoflavones.

Our one-line summary comes first. The original is on PubMed.

Show the 10 studies
  • Over 2 years, bone loss did not differ from a dummy tablet; more women had hot flashes with soy isoflavones.

    Trial · enrollment in the trial registry, NCT00076050 · 2 years

    Levis et al., Archives of Internal Medicine, 2011

    Terms and sources
    Over 2 years
    248 women aged 45 to 60, within 5 years of menopause, at one center. A bone density T-score of −2.0 or higher was required.
    bone loss did not differ
    Spine: −2.0% with soy and −2.3% with the dummy tablet. Total hip: −1.2% and −1.4%. Femoral neck: −2.2% and −2.1%. The differences were not statistically significant.
    a dummy tablet
    The trial was double-blind.
    more women had hot flashes
    The abstract reports more "hot flashes and constipation" in the soy group. The differences were statistically significant. Vaginal cell tests, a bone marker, lipids and thyroid tests did not differ.
    soy isoflavones
    200 mg a day in tablets. Europe PMC lists an NIH grant (NIAMS) as the funder. We could not read who supplied the tablets. An invited commentary, a letter with an author reply and a comment in another journal were published. We could not read them.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A single-center trial enrolled 248 women within 5 years of menopause. They took 200 mg of soy isoflavones or a dummy tablet daily for 2 years. Bone density fell in both groups. At the spine it fell 2.0% with soy and 2.3% with the dummy tablet. Neither this nor the hip results differed statistically. The abstract reports more "hot flashes and constipation" in the soy group. Other outcomes did not differ. Funding: Europe PMC lists an NIH grant.

  • Bone loss over 3 years did not differ from a dummy tablet, except at one hip site after adjustment.

    Trial · 224 in the intent-to-treat analysis · 3 years · maker-supplied

    Alekel et al., American Journal of Clinical Nutrition, 2010

    Terms and sources
    Bone loss over 3 years
    255 healthy women aged 45.8 to 65 after menopause were randomized at two sites. Women with low or high bone density were excluded. They took 80 or 120 mg of soy isoflavones a day in tablets. All groups also took 500 mg of calcium and 600 IU of vitamin D3.
    did not differ
    Spine, total hip, femoral neck and whole body. This held for all women and for those who took most tablets. Bone density fell in all groups. Bone markers, endometrial thickness and adverse events did not differ either. Two more reports of this trial: endometrium and hormones did not differ; bone strength differed only in some adjusted models.
    a dummy tablet
    The trial was double-blind.
    except at one hip site after adjustment
    In women who took most tablets, the analysis was adjusted for age, body fat and a bone resorption marker. In it, 120 mg differed from the dummy tablet at the femoral neck. The authors call this a modest effect.
    maker-supplied
    Archer Daniels Midland supplied the isoflavone ingredients, NovaSoy, free of charge, per the acknowledgments. The trial was funded by NIH, per the methods. One author sits on the scientific advisory board of the Soy Nutrition Institute.

    Study · Free full text · about 40 min to read

    Our estimate at about 200 words a minute, from the PMC full text.

    Study summary

    A trial at two sites randomized 255 healthy women after menopause. They took 80 or 120 mg of soy isoflavone tablets or a dummy tablet for 3 years. All groups also took calcium and vitamin D3. In the main analysis, bone loss at the spine, hip and whole body did not differ. After adjustment for age, body fat and a bone marker, 120 mg differed at the femoral neck. The authors call this effect modest. Funding: NIH; Archer Daniels Midland supplied the isoflavones.

  • Over 2 years, whole-body bone loss was smaller with 120 mg of soy germ isoflavones; regional sites did not differ.

    Trial · 135, 135 and 136 randomized (results); the abstract and the registry give 403 · 2 years · maker-supplied

    Wong et al., American Journal of Clinical Nutrition, 2009

    Terms and sources
    Over 2 years
    406 women aged 40 to 60, at least 12 months after their last period, at three centers. Women with low spine bone density were excluded. All took calcium and a multivitamin with vitamin D. The abstract and the registry give 403.
    smaller
    Smaller than with the dummy tablet, at 1 and 2 years, after adjustment for site, soy intake and starting values. The difference was statistically significant. The report gives it for 120 mg.
    soy germ isoflavones
    Three tablets a day. Each held 40.51 mg of isoflavones, mostly daidzein and glycitein, with 4.96 mg of genistein. The dummy tablets held cellulose.
    regional sites did not differ
    Regional bone density and mineral content, T scores and bone markers did not differ from the dummy tablet. A second report of this trial found no difference in endometrial thickness. Blood urea nitrogen rose at 2 years with isoflavones; all blood values stayed in the normal range. Two serious adverse events occurred, both in isoflavone groups. The second report calls this fewer than expected for the population.
    maker-supplied
    Frutarom Netherlands made the soy germ isoflavones, and Pharma Consulting & Industries made the tablets, per the methods. The article says the makers were not involved in design or analysis. PubMed lists an NIH grant (NCRR).

    Study · Free full text · about 20 min to read

    Our estimate at about 200 words a minute, from the PMC full text.

    Study summary

    A multicenter trial randomized 406 women after menopause. They took 80 or 120 mg of soy germ isoflavones or a dummy tablet daily for 2 years. All took calcium and vitamin D. With 120 mg, whole-body bone loss was smaller than with the dummy tablet at 1 and 2 years. Regional bone density, mineral content and bone markers did not differ. Funding: an NIH grant; Frutarom made the isoflavones.

  • For a year, women ate foods with 110 mg of isoflavones or dummy foods; bone density did not differ.

    Trial · as given in the abstract · 1 year · funding not stated

    Brink et al., American Journal of Clinical Nutrition, 2008

    Terms and sources
    women
    237 healthy early postmenopausal women, mean age 53, at several centers. They kept their usual diet.
    foods with 110 mg of isoflavones
    Isoflavone-enriched foods, 110 mg of isoflavone aglycones a day on average. Blood and urine isoflavones rose only with these foods.
    dummy foods
    Control products, per the abstract. The trial was double-blind.
    bone density did not differ
    Spine and total body. Bone markers and hormones did not differ either, nor did safety tests and adverse events.
    funding not stated
    PubMed's record lists funding from sources other than the US government. We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A multicenter trial gave 237 healthy women in early menopause foods enriched with isoflavones or control foods for a year. The enriched foods gave 110 mg of isoflavones a day. Blood and urine isoflavones rose only in that group. Bone density at the spine and whole body did not differ. Bone markers, hormones and safety tests did not differ either. Funding: we could not read the funding section.

  • For 12 weeks, moderate-to-severe hot flashes fell more with 80 mg of soy isoflavones than with a dummy tablet.

    Trial · as given in the abstract · 12 weeks · funding not stated

    Ferrari, Journal of Obstetrics and Gynaecology Research, 2009

    Terms and sources
    moderate-to-severe hot flashes
    180 women aged 40 to 65, without periods for at least 6 months. They had 5 or more moderate-to-severe hot flashes in the past 7 days. The trial ran at several centers.
    fell more
    At 12 weeks, daily moderate-to-severe hot flashes fell 41.2% with isoflavones and 29.3% with the dummy tablet. The difference was 1.1 a day and statistically significant, also at 6 weeks. The Kupperman index fell in both groups; the abstract gives no comparison.
    80 mg of soy isoflavones
    One tablet a day, with 60 mg of genistein, from a soy extract. The abstract does not name the maker.
    a dummy tablet
    A matching placebo tablet. The trial was double-blind.
    funding not stated
    We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A multicenter trial enrolled 180 women after menopause. They took one soy isoflavone tablet or a dummy tablet a day for 12 weeks. Each had at least 5 moderate-to-severe hot flashes in the week before. The tablet held 80 mg of isoflavones with 60 mg of genistein. At 12 weeks, these hot flashes fell 41.2% with isoflavones and 29.3% with the dummy tablet. The difference was statistically significant. Funding: we could not read the funding section.

  • Over 12 weeks, hot flashes with soy germ isoflavones differed from a dummy capsule only for both doses combined.

    Trial · randomized per the abstract; the methods give 191 · 12 weeks · maker-funded

    Khaodhiar et al., Menopause, 2008

    Terms and sources
    Over 12 weeks
    190 women aged 38 to 60 with 4 to 14 hot flashes a day were randomized, per the abstract. The methods give 191 women and up to 15 hot flashes. 147 completed the trial. Entry required no periods for 6 months, yet the report counts 28 completers as perimenopausal.
    hot flashes
    At 12 weeks, hot flashes fell 52% with 40 mg, 51% with 60 mg and 39% with the dummy capsule. Neither dose alone differed statistically from the dummy capsule. Both doses together did at 12 weeks, not at 8 weeks. Quality of life, hormones, thyroid tests and lipids did not differ.
    soy germ isoflavones
    40 or 60 mg of aglycones a day in a soft-gel capsule, AglyMax. The extract came from soy germ fermented with a koji fungus; it was mostly daidzein. The report lists "gastrointestinal" side effects with the extract; two women on 60 mg stopped for them. It also says no woman reported major side effects.
    a dummy capsule
    A placebo soft-gel capsule. The trial was double-blind.
    maker-funded
    Nichimo Co., which made the extract, paid for this trial, per the article. PubMed also lists an NIH center grant.

    Study · Free full text · about 21 min to read

    Our estimate at about 200 words a minute, from the PMC full text.

    Study summary

    A trial randomized 190 women with 4 to 14 hot flashes a day. They took 40 or 60 mg of soy germ isoflavones or a dummy capsule for 12 weeks. Hot flashes fell 52% and 51% with the two doses and 39% with the dummy capsule. Each dose alone did not differ statistically from the dummy capsule. Both doses combined did. Funding: Nichimo Co., the maker of the extract.

  • Over 24 weeks, hot flashes and symptom scores fell more with soy germ isoflavones than with a dummy product.

    Trial · 30 per group · 24 weeks · funding not stated

    Ye et al., Menopause, 2012

    Terms and sources
    Over 24 weeks
    90 Chinese women aged 45 to 60, early after menopause. The bone report of the same trial gives the entry rule: a Kupperman score above 15. Its bone report found no difference between groups, only a trend with the dose. A letter on this trial was published; we could not read it.
    hot flashes and symptom scores fell more
    Hot flashes fell 44.3% and 48.5% with 84 and 126 mg, and 27.8% with the dummy product. The Kupperman index fell 57.8% and 56.7%, and 34.6%. The differences were statistically significant.
    soy germ isoflavones
    84 or 126 mg a day. Estradiol, the hormones FSH and LH, and blood lipids did not differ from the dummy product.
    a dummy product
    Placebo; the abstract does not describe its form. The bone report of this trial calls it single-blind.
    funding not stated
    We could not read the funding section of this paper. PubMed gives an affiliation only for the first author, a university in Guangzhou.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A trial in Guangzhou enrolled 90 women early after menopause. They took 84 or 126 mg of soy germ isoflavones or a dummy product for 24 weeks. Hot flashes and the Kupperman symptom score fell in all groups. The falls were statistically significantly larger with both doses. Hormones and blood lipids did not differ. The bone report of this trial calls it single-blind. Funding: we could not read the funding section.

  • Over 10 months, hot flashes fell more with 100 mg of soy isoflavones than with a dummy product.

    Trial · 40 per group · 10 months · funding not stated

    Nahas et al., Maturitas, 2007

    Terms and sources
    Over 10 months
    80 women after menopause, mean age 55.1, with 5 or more hot flashes a day. Women for whom hormone therapy was ruled out were excluded.
    hot flashes fell more
    Daily hot flashes went from 9.6 to 3.1 with isoflavones and from 10.1 to 5.9 with the dummy product. The difference was statistically significant. Severity fell 69.9% and 33.7%. The Kupperman index fell in both groups.
    100 mg of soy isoflavones
    250 mg a day of a standardized soy extract, Glycine max AT. Endometrial thickness, mammograms, vaginal cells, lipids and hormones did not change in either group.
    a dummy product
    Placebo; the abstract does not describe its form. The trial was double-blind.
    funding not stated
    PubMed's record lists funding from sources other than the US government. We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A trial in Brazil randomized 80 women after menopause with 5 or more hot flashes a day. They took 250 mg of a soy extract with 100 mg of isoflavones, or a dummy product, for 10 months. Daily hot flashes went from 9.6 to 3.1 with isoflavones and from 10.1 to 5.9 with the dummy product. The difference was statistically significant. Lipids, hormones and the endometrium did not change. Funding: we could not read the funding section.

  • Taking 60 mg of isoflavones and a dummy capsule one after the other, women's hot flashes did not differ.

    Trial · Study A; Study B had 28 more women · 24 weeks · funding not stated

    Campagnoli et al., Maturitas, 2005

    Terms and sources
    women's hot flashes
    29 women after menopause with more than five troublesome hot flashes a day.
    60 mg of isoflavones
    Two capsules a day of a soy isoflavone extract. In a second trial in the same report, all women also took a fatty-acid supplement. Isoflavones again did not differ from the dummy capsule.
    a dummy capsule
    Placebo capsules. The trial was double-blind.
    one after the other
    12 weeks of each, in random order (crossover).
    did not differ
    The isoflavone extract showed no greater effect on hot flashes than the dummy capsule.
    funding not stated
    PubMed's record lists funding from sources other than the US government. We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A trial in Turin enrolled 29 women after menopause. They took 60 mg of soy isoflavones and a dummy capsule, one after the other, for 12 weeks each. Each had more than five troublesome hot flashes a day. Hot flashes did not differ between the two periods. A second trial in the same report added a fatty-acid supplement for all women, with the same result. Funding: we could not read the funding section.

  • Women took 80 mg of soy isoflavones or a dummy product for 6 months; thinking test scores did not differ.

    Trial · 191 people · 6 months · funding not stated

    Ho et al., Menopause, 2007

    Terms and sources
    Women
    191 Chinese women aged 55 to 76 after menopause, living in the community. 168 completed the trial.
    80 mg of soy isoflavones
    A soy-derived isoflavone extract taken by mouth. The abstract does not name the maker.
    a dummy product
    An identical-appearing placebo. The trial was double-blind.
    thinking test scores did not differ
    Tests of memory, attention, planning, motor control, language and visual perception, and a global score. Quality of life did not differ either. Complaints were similar in both groups, mainly digestive and joint or muscle ones.
    funding not stated
    We could not read the funding section of this paper. PubMed's record lists funding from sources other than the US government.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A trial in Hong Kong enrolled 191 women aged 55 to 76 after menopause. They took 80 mg of soy isoflavones or a dummy product daily for 6 months. Tests covered memory, attention, planning, motor control, language and visual perception. No test score differed between groups. Quality of life did not differ either. Complaints were similar in both groups. Funding: we could not read the funding section.

Sources

Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.